药理学研究与展望 SCIESCI

期刊简介预计审稿时间：20 Weeks

PR&P is jointly published by the American Society for Pharmacology and Experimental Therapeutics (ASPET), the British Pharmacological Society (BPS), and Wiley. PR&P is a bi-monthly open access journal that publishes a range of article types, including: target validation (preclinical papers that show a hypothesis is incorrect or papers on drugs that have failed in early clinical development); drug discovery reviews (strategy, hypotheses, and data resulting in a successful therapeutic drug); frontiers in translational medicine (drug and target validation for an unmet therapeutic need); pharmacological hypotheses (reviews that are oriented to inform a novel hypothesis); and replication studies (work that refutes key findings [failed replication] and work that validates key findings). PR&P publishes papers submitted directly to the journal and those referred from the journals of ASPET and the BPS

PR&P 由美国药理学和实验治疗学会 (ASPET)、英国药理学会 (BPS) 和 Wiley 联合出版。 PR&P 是一个双月刊开放获取期刊，发表一系列文章类型，包括：目标验证（显示假设不正确的临床前论文或早期临床开发失败的药物论文）；药物发现审查（导致成功治疗药物的策略、假设和数据）；转化医学的前沿（针对未满足的治疗需求的药物和靶点验证）；药理学假设（旨在为新假设提供信息的评论）；和复制研究（驳斥关键发现的工作[失败的复制]和验证关键发现的工作）。 PR&P 发表直接提交给期刊的论文以及从 ASPET 和 BPS 期刊引用的论文

《Pharmacology Research & Perspectives》(药理学研究与展望)编辑部通讯方式为THE ATRIUM, SOUTHERN GATE, CHICHESTER, ENGLAND, W SUSSEX, PO19 8SQ。如果您需要协助投稿或润稿服务，您可以咨询我们的客服老师。我们专注于期刊投稿服务十年，熟悉发表政策，可为您提供一对一投稿指导，避免您在投稿时频繁碰壁，节省您的宝贵时间，有效提升发表机率，确保SCI检索（检索不了全额退款）。我们视信誉为生命，多方面确保文章安全保密，在任何情况下都不会泄露您的个人信息或稿件内容。